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Abstract
Mesenchymal stem cells (MSC) represent a promising cellular therapy for the treatment of immune-related
conditions due to their immunomodulatory properties, which include the capacity to inhibit the proliferation and
function of T-cells. Despite the fact that MSC have been the subject of intense investigation as therapeutic agents
for diseases in which cellular immune response is exacerbated, the underlying mechanisms of how MSC exert their
Tcell suppressive properties remain to be fully understood. Eph surface tyrosine kinase receptors and their ephrin
ligands are involved in T-cell development, maturation, activation and proliferation. Recent findings have
demonstrated Eph/ephrin interactions as potential mechanisms mediating human MSC inhibition of activated T-cells.
Here we highlight the influence of Eph and ephrin molecules in the communication between MSC and T-cells that
result in T-cell suppression by MSC.
Definition and Characteristics of Mesenchymal Stem
Cells
Mesenchymal stem cells (MSC) are self-renewing stem cells
identified in rodent and human bone marrow aspirates based on their
ability to form adherent clonogenic clusters (CFU-F; colony forming
units-fibroblastic) in vitro, and by their capacity to differentiate into
multiple specialized mesodermal cell lineages [1-4]. Similar MSC-like
populations have been described in various tissues with different
growth and differentiation potentials [5-7]. These MSC-like
populations share a common immunophenotype based on the cell
surface expression of various markers, but not limited, to STRO-1,
CD73, CD105, CD106, CD90, CD146 and CD166, while lacking
expression of CD34, CD3, CD14, CD19, CD31, CD34, CD45,
Glycophorin-A and HLA-DR [2,3,8-10]. In the last few decades, MSC
have generated considerable interest due to their production of
cytokines and growth factors, which act as potent mediators of
angiogenesis, regeneration of damaged tissues, hematopoiesis and
immune cell responses [11-17]. In particular, the paracrine properties
of MSC, makes them highly desirable as potential cellular therapies to
treat a variety of immune/inflammatory based diseases and conditions.
MSC mediated regulation of T-cell proliferation and
activation
The role of MSC in modulating immune responses has been
demonstrated both in vitro and in vivo [13,18]. Multiple studies have
shown that MSC profoundly modulate immune response through their
interactions with the cellular components of the innate (natural killer
cells, dendritic cells) and adaptive (B-cells, T-cells) immune system
(Figure 1). MSC are known to be weakly immunogenic due to the lack
of expression of MHC class II antigen and co-stimulatory molecules
such    as   CD40,  CD80,  CD86  or  CD40L [13].   Whilst  MSC  have  a
Figure 1: Immunomodulatory properties of MSC. MSC modulate
the response of a broad range of immune cells including B-cells, NK
cells, DC and T-cells. NK: Natural Killer cells, DC: Dendritic cells,
T-reg: T-regulatory cells, Th: T-helper cells, HLA: Human leukocyte
antigen; IL: Interleukin; IFNγ: Interferon-gamma; TNF-α: Tumour
Necrosis Factor-alpha; IDO: Indoleamine 2,3-dioxygenase; HGF:
Hepatocyte Growth Factor; TGF-β1: Transforming Growth Factor-
β; IL-10: Interleukin 10; PGE2: Prostaglandin E2; NO: Nitric Oxide.
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reduced   capacity  to  trigger  T-cell  activation,   they  exhibit   a  potent
capacity to inhibit T-cell proliferation and function either directly
through cell–cell contact or indirectly via the secretion of various
factors. Due to these properties, MSC are protected from natural killer
cellmediated killing and have the ability to escape immunosurveillance
and regulate immune cell/inflammatory responses.
Studies investigating the hypoimmunogenic properties of MSC have
reported that ex vivo expanded third party human MSC suppress T-
cell proliferation stimulated by allogeneic peripheral blood
mononuclear cells (PBMNC) and allogeneic splenocytes, activated
with mitogens such as, concanavalin A, anti-CD3, anti-CD28
antibodies or with IL-2, IL-7 or IL-15 in vitro [19,20]. It has been
demonstrated that both CD4 and CD8 T-cells are equally inhibited by
MSC in a dose-dependent manner. Most significantly, MSC do not
induce T-cell apoptosis but rather facilitate a shutdown in
proliferation/activation [21]. Indeed, the anti-proliferative effects of
MSC on T-cell populations only occurs when T-cells are activated [22].
However, direct contact between MSC and activated T-cells leads to T-
cell arrest in the G0 phase of the cell cycle. MSC induce T-cells to enter
an anergic state, characterized by an absence of proliferation and
cytokine production in response to antigenic stimulation, generally as
a result of insufficient co-stimulation [23,24]. Furthermore, other
studies have reported that MSC cause a reduction in the expression of
the early activation markers CD25 and CD69, while others found no
change in expression of these markers [20,25]. The discrepancies of
these findings could potentially relate to the variations in
subpopulations of MSC that were being investigated and the
differences in the population of T-cell studied.
In the last decade, it has become evident that multipotent human
MSC, exhibiting immunomodulatory properties, are being utilized in
various clinical trials to treat various immunological conditions
including steroid-resistant acute graft-versus-host disease (GvHD)
following hematopoietic stem cell transplantation, inflammatory bowel
diseases, encephalomyelitis and allograft rejection after solid organ
transplantation [18,26,27]. To date, numerous cell based-therapies
employing MSC to treat diseases in which cellular immune responses
are exacerbated, have been registered at clinical-trials.gov (https://
clinicaltrials.gov/ct2/results?term=%22mesenchymal+stem+cell%22+
AND+%22immune+disease%22&Search=Search).   Most  significantly,
the  use  of   MSC  to   treat   paediatric  patients with steroid refractory
acute    GvHD    has    been    approved    in    Japan    (TEMCELL,®   JCR
Pharmaceuticals) [28], Canada and New Zealand (Prochymal®; Osiris
Therapeutics) [29].
Despite extensive documentation of the interactions between MSC
toward different Tcell subpopulations, the exact mechanisms
underlying these processes remain unclear. Recent studies indicate that
multiple immunosuppressive factors can be released or expressed by
MSC and the nature of these factors is dependent on the type of stimuli
received by MSC, such as allogeneic determinants, membrane-bound
proteins, mitogens and cytokines [27,30]. Several independent studies
have indicated that hepatocyte growth factor (HGF), transforming
growth factor-β1 (TGF-β1), indoleamine 2,3-dioxygenase (IDO),
prostaglandin E2 (PGE2), HLA-G5 and IL-10 are all key players in
MSC-mediated immunosuppression in vitro [30,31]. Other studies
have suggested that contact-dependent mechanisms are involved,
including the B7-H1/PD-1 pathway [13,18]. While some of these
factors partially contribute to the immunomodulatory properties of
MSC, the underlying mechanisms that regulate MSC mediated
immune cell action are far more complex than initially thought.
More recently, the tyrosine kinase receptors, Eph (Erythropoietin-
producing hepatocyte kinases) and their ligands, ephrin (Eph receptor
interaction proteins) have been reported to be involved in MSC
attachment, migration, differentiation, bone remodeling, fracture
repair and hematopoietic support [11,32-35]. Studies have also
demonstrated that Eph/ephrin tyrosine kinase molecules play an
important role in the development and function of immune cells
[36-39], including, T-cell populations [40-42].
Eph and ephrin molecules
Eph receptors and their ephrin ligands represent the largest group of
receptor tyrosine kinases [43] and are known to be involved in the
regulation of numerous biological systems in which cell–to–cell
interactions are particularly relevant [44,45]. The Eph receptors are
membrane bound proteins and are divided into EphA (10 members)
and EphB (6 members) subclasses based on their binding affinity to
either ephrinA (6 members) or ephrinB (3 members) ligands (Figure
2). The EphA and EphB receptors share similar structural homology
Figure 2: The structure of the Eph receptors and their ephrin
binding ligands. GPI: Glycosyl Phosphatidylino-sitol; PDZ: Post-
synaptic density, disc large, zona occludens-1; LBD: Ligand Binding
Domain; CRD: Cysteine Rich Domain; FNIII: Fibronectin III; JR:
Juxtamembrane Region; SH2: SRC Homology 2; SAM: Sterile Alpha
Motif; PBM: PDZ Binding Motif.
[46],  composed  of   extracellular  and  cytoplasmic  components.   The
extracellular portion of the Eph receptor consists of an amino terminal
ligand binding domain, a cysteine rich region and two fibronectin type
III repeats [43]. The cytoplasmic region of the Eph receptor contains
SRC homology 2 binding sites, a juxtamembrane region, a tyrosine
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kinase domain, a sterile alpha motif (SAM) proteinprotein interaction
domain, and a post-synaptic density, disc large, zona occludens-1
(PDZ) binding motif [47]. Each region is important for signalling in
different situations, the juxtamembrane domain contains two
conserved tyrosine residues (tyrosine and serine) which become
phosphorylated upon the binding of ephrin ligand, allowing the
intracellular tyrosine kinase domain to convert into its active form and
activate or repress downstream signalling cascades, whereas the role of
the SAM domain is in protein–protein interactions. The PDZ domain
consists of a binding sequence which has a hydrophobic residue
(generally valine or isoleucine) at the carboxyl terminus, that also
functions in protein–protein interactions [48]. Both subclasses of the
ephrin ligands consist of an extracellular Eph-receptor binding
domain, however, the structure of the ligands differs between
subclasses [49]. The ephrinA ligands are GPI linked to the membrane,
where the GPI anchor is composed of one molecule of
phosphatidylinositol, which has a carbohydrate chain link through the
C-6 hydroxyl of the inositol. The GPI anchor functions to attach the
ephrinA ligand to the exoplasmic leaflet of the membrane and to other
specific domains inside the cell [48]. Conversely, ephrinB ligands are
transmembrane proteins with a short cytoplasmic tail, which contains
functional tyrosine kinase phosphorylation sites and an intracellular
PDZ binding motif [49].
Eph/ephrin signalling is highly complex due to the high number of
members and promiscuity of individual Eph receptors binding to
multiple ligands and vice versa, albeit with distinct affinities [43].
While the Eph molecules are regarded as the receptor and the ephrin
molecules as the ligand, Eph/ephrin-mediated interactions can result
in both forward signalling through the Eph receptor expressing cell
and reverse signalling through the ephrin-expressing cell, and/or
bidirectional signalling in both Eph and ephrin expressing cells. As a
result, Eph/ephrin interactions often provide different cell responses
depending on the multiple combinations and directions of signalling.
In the context of T-cell biology, Eph/ephrin interactions activate
numerous signalling pathways that regulate T-cell progenitor
recruitment to the thymus [50], thymocyte development and
maturation within the thymic microenvironment [51], T-cell co-
stimulation, activation and proliferation (Table 1). More recently,
members of the EphB subclass are involved in MSC-mediated
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double knockout ephrinB1 and
ephrinB2 mice specifically in the T-cell
compartment resulted in reduced
thymus and spleen size and cellularity,
and compromised T-cells homeostatic
expansion
[36]
EphB2 EphB2deficient mice exhibited thymic
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activated T-cells.
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communication between human MSC
and T-cells inhibit T-cell proliferation
[52]
MSC: Mesenchymal Stem Cells
Table 1: Regulation of T-cell development and function by Eph/ephrin
interactions.
Eph/ephrin-mediated MSC suppression of activated T-cells
Cell–to–cell contact represents one of the main mechanisms
involved in T-cell suppression by MSC [16]. Various studies exploring
the dynamics of MSC and T-cell interactions reported that cell–to–cell
contact produced a stronger MSC-mediated suppressive effect on T-
cell proliferation/activation [17,53]. Indeed, a number of MSC
expressing membrane molecules such as integrins (α1, α2, α3, α5, α6,
αv, β1, β3 and β4), intercellular adhesion molecules (ICAM-1,
ICAM-2), vascular cell adhesion protein (VCAM-1), CD72 and CD58
(LFA-3) that bind to T-cells with high affinity. In addition, a number of
membrane molecules participate in MSC-mediated immunoregulation
include the B7-H1/PD-1 pathway, HLA-G1 and Jagged-1 [16,17].
Eph and ephrin, contact-dependent molecules involved in T-cell
biology and MSC regulation, have only recently been demonstrated to
play an important role in MSCmediated suppression of T-cell
proliferation. Human primary T-cells express high levels of ephrinB1
and EphB4 [52], which bind with highest affinity to EphB2 and
ephrinB2, respectively, which are highly expressed by human MSC
[32], emphasizing a role of EphB2/ephrinB1 and EphB4/ephrinB2
interactions in MSC–T-cell communication. This is in accord with
previous studies demonstrating that ephrinB1 and ephrinB2
suppressed murine Tcell proliferation [42], and that EphB2 and
ephrinB2 interactions significantly suppressed human T-cell
proliferation, in allogeneic mixed lymphocyte cultures [52]. Of note,
the EphB2 and ephrinB2-mediated T-cell suppression of MSC was
reversed in experiments using EphB2 and EphB4 blocking peptides, to
disrupt the EphB2/ephrinB1 and ephrinB2/EphB4 interactions,
respectively, between MSC and T-cell populations. The functional role
of EphB2 and ephrinB2 in T-cell suppression of MSC was further
confirmed in shRNA knockdown studies of either EphB2 or ephrinB2
in human MSC, which resulted in a decreased capacity to suppress T-
cell proliferation, compared with non-silencing shRNA scrambled
control MSC [52]. These findings are supported by investigations
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utilizing double knockout ephrinB1 and ephrinB2 mice specifically in
the T-cell compartment (through loxPmediated gene deletion), which
resulted in reduced thymus and spleen size and cellularity, and
compromised T-cells expansion [36]. Furthermore, EphB2-deficient
mice revealed that thymic hypo-cellularity was associated with altered
survival and proliferation of the differentiating lymphocytes, evident
by a decrease in the double positive and single positive thymocyte
subpopulations and mature CD4+ and CD8+ Tcell populations [54].
Interestingly, contradictory studies reported that members of the
EphB-subclass act as co-stimulatory molecules for murine T-cell
proliferation [42,55-57]. The ephrinB2 ligand was shown to stimulate
T-cell function by enhancing T-cell response to antigens by in vitro
TCR stimulation [56]. In EphB6 knockout studies, T-cells were
reported to be defective in their response to TCR stimulation in vitro
and in vivo [57]. Furthermore, ephrinB1 was found to be crucial in T-
cell–to–T-cell co-operation in response to antigen stimulation, while
ephrinB2 and ephrinB3 were found to play a role in T-cell co-
stimulation to enhance T-cell signaling [58]. In rheumatoid arthritis,
EphB1/ephrinB1 interactions were demonstrated to enhance T-cell
migration [59]. Therefore, the contribution of Eph/ephrin molecules
during T-cell proliferation remains controversial. Nevertheless, it must
be highlighted that whilst Eph/ephrin molecules constitute a large
family with many members that bind promiscuously to each other,
both Eph receptors and ephrin ligands have their own signalling
mechanisms that interact with many other signalling pathways (such
as MAPK, PI3K, Src, Pyk2) adding to the variability of biological
responses. Therefore, Eph/ephrin signalling is associated with a
complicated network of agonistic or antagonistic cross-talk, even
between the same Eph/ephrin pairings, and is highly dependent on the
cell types and their state of differentiation.
In the context of T-cell proliferation, Kawano and colleagues have
demonstrated a switch from T-cell stimulation to suppression of
proliferative responses in the presence of ephrinB1-Fc and ephrinB2-
Fc fusion molecules by varying the concentrations [42], indicating
EphB/ephrinB signalling in T-cell activation involves a concentration-
dependent switch from co-stimulation to inhibition. Furthermore, the
findings that MSC expressing EphB2 or ephrinB2 inhibits T-cell
proliferation are in agreement with other studies, which found that
EphA/ephrinA interactions inhibit activated CD4+ T-cell proliferation
and T-helper-2-cell activation [60], while ephrinB1 and ephrinB2
compromise STAT3 activation leading to a decreased T-cell
proliferation [36]. Notably, the immunosuppressive effects of MSC
mediated by EphB2 and ephrinB2 was independent of T-cell apoptosis,
consistent to other findings that MSC do not appear to induce T-cell
cell death [17,53]. Therefore, EphB2/ephrinB1 and ephrinB2/EphB4
interactions can be considered as additional mechanisms of cross-talk
between MSC and T-cells, revealing the importance of cell adherence
in the context of immunomodulation by MSC.
The role of ephrinB1 and ephrinB2 in homeostatic expansion of T-
cells have also been reported [36]. Mice with double conditional
knockout of both ephrinB1 and ephrinB2 (through loxP-mediated
gene deletion) presented failed homeostatic expansion in sub-lethally
irradiated recipients. This effect was thought to be mediated by
reduced IL-6 signalling in the T-cell compartment. These findings were
consistent to another study showing that IL-6 is required for the
survival of naïve T-cells during homeostatic expansion [61].
Mechanisms of Eph/ephrin-mediated MSC suppression of
activated T-cells
In addition to cell–to–cell contact, MSC exert their
immunomodulatory effects by releasing soluble factors [13,15]. The
production of suppressive soluble factors is dependent on cross-talk
between MSC and activated T-cells since the use of conditioned
supernatant from MSC cultures is not sufficient to elicit T-cell
suppression, in contrast to condition media from MSC co-cultured
with activated T-cells. Similar levels of activated T-cell suppression can
also be seen using conditioned media from MSC cultures, following
pre-stimulated with T-cell derived factors such as IFNγ [18].
Treatment of MSC with IFNγ have been reported to stimulate MSC
production of IDO [18,21,27], where MSC lacking the IFN-γ receptor
lose their capacity to suppress T-cell proliferation [21]. Recent findings
have shown that EphB2 and ephrinB2 mediate MSC suppression of T-
cells by their capacity to secrete elevated levels of IDO expression
following activation of EphB4 or ephrinB1 expressing T-cells in the
presence of IFN-γ [52]. In addition, the expression of other
immunomodulatory factors, TGF-β1 and iNOS, were also reported to
be up-regulated following stimulation with EphB4 expressing human
T-cells [52]. Induction of iNOS expression correlated with elevated
levels of NO, as iNOS is induced by cytokines for the synthesis of NO
[62]. Other soluble factors produced by T-cells, such as TNF-α, IL-2,
IL-17 and IL-4 are vital for T-cell activation and proliferation [63].
While MSC have been demonstrated to suppress Tcell proliferation by
reducing IL-17 production [64], TNF-α, IL-2 and IL-17, but not IL-4,
expression levels were down-regulated in human T-cells following
stimulation with EphB2 and ephrinB2, expressed by human MSC [52].
Moreover, stimulation of murine T-cells with ephrinB2 suppressed
their proliferation associated with a reduction of TNF-α, IL-2 and
IL-17 [42]. However, the expression levels of HGF and IL-10, also
known to be involved in MSC mediated immunosuppression of T-cells,
were not affected by EphB4 or ephrinB1 stimulation, indicating a level
of specificity in EphB/ephrinB signalling during MSC and T-cell
interactions.
While Eph/ephrin interactions trigger numerous signalling
pathways to mediate T-cell migration, maturation, proliferation and
differentiation, it appears that the underlying mechanisms of Eph/
ephrin-mediated T-cell suppression by human MSC were through
EphB2induced ephrinB1 reverse signalling and ephrinB2-induced
EphB4 forward signalling in activated T-cells[52]. Experiments
employing signalling inhibitors showed that inhibition of T-cell
proliferation is mediated through activation of Src family kinase, PI3
Kinase, JNK and Abl kinases signalling pathways. Conversely,
inhibitors to the MEK, p38 MAPK pathways failed to elicit any
significant changes in EphB4 forward signalling or ephrinB1 reverse
signalling mediated suppression of T-cell proliferation. Whilst ephrinB
reverse signalling has previously been described to be mediated via the
Src molecule, Grb4, the PDZ domain or through the JNK pathway
independent of tyrosine kinase phosphorylation [65,66], recent
findings have demonstrated that reverse ephrinB signalling inhibited
MSC attachment and spreading by activating Src, PI3 Kinase and JNK-
dependent signalling pathways [32]. In addition, the Eph family are
mediated predominantly through their tyrosine kinase activity and
receptor phosphorylation [67], where ephrinB2-mediated suppression
of T-cell proliferation was promoted by phosphorylation of EphB4 in
T-cells activated by allogeneic MLR. Similarly, EphB2-mediated
suppression of T-cell proliferation was also dependent on tyrosine
phosphorylation during ephrinB1 reverse signalling. This is consistent
with the finding of Kawano et al. describing that ephrinB2 inhibits
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primary murine T-cell proliferation by inducing EphB4
phosphorylation [42].
The role of EphB2 and ephrinB2 interactions in MSC mediated
suppression of activated T-cells appears to be quite specific. In addition
to EphB2 and ephrinB2, MSC also express EphB4, ephrinB1, EphA2
and ephrinA5 that can promiscuously bind to various Eph and ephrin
molecules expressed by T-cells. Studies examining the functional role
of these Eph/ephrin molecules in Tcell proliferation demonstrated that
T-cell proliferation was unaffected in the presence of these molecules
[52]. This work confirmed the high affinity binding of MSC expressing
EphB2 and ephrinB2 to ephrinB1 and EphB4 respectively, which are
highly expressed by human T-cells. Furthermore, T-cells were found to
express high gene expression levels of EphA4, which is known to
promiscuously bind to ephrinA5 expressed by MSC [48,49]. However,
functional studies showed no difference in T-cell proliferation in the
presence of inhibitor to EphA4 receptor, supporting the notion that
EphA and ephrinA molecules, are not directly involved in MSC-
mediated suppression of activated T-cells. Human T-cells also express
ephrinB3, which is known to bind to EphB2 [46]. However, it appears
that ephrinB3 is unlikely to be involved in EphB2 mediated inhibition
of Tcell proliferation. This is consistent with a previous report
suggesting that ephrinB3 plays a stimulatory role in murine T-cell
proliferation induced by anti-CD3, while ephrinB1 and ephrinB2
strongly inhibit murine activated T-cell proliferation [42]. Collectively,
these findings suggest a role for EphB/ephrinB molecules in mediating
MSC suppression of activated T-cells (Figure 3).
In addition to cell–to–cell contact and release of soluble factors,
generation of regulatory T-cells has also been one of the main
mechanisms involved in T-cell suppression by MSC [13]. Regulatory
T-cells (Tregs), also known as suppressor T-cells, express the
immunophenotype, CD4+CD25+FoxP3+, and play an important role in
the maintenance of immunological tolerance to suppress auto-
immunity and graft rejection [24]. Co-culture of MSC with naïve T-
cells in mixed allogeneic lymphocyte reactions results in an increase in
the number of Treg cells [68,69]. Similarly, in an in vivo setting, it was
reported that circulating Tregs increased in number when MSC were
used in the treatment of systemic lupus erythematosus or in a kidney
allograft in mice [69,70]. In these studies, MSC contributed to the
expansion of the existing Treg populations. It appears that MSC act as
a “homeostatic niche” for Tregs, to recruit, regulate and maintain Treg
phenotype and function. While the interactions of EphB2/ephrinB1
and ephrinB2/EphB4 between MSC and T-cells play an important role
in MSC-mediated Tcell suppression, their role in MSC stimulation of
Tregs have yet to be identified. Studies have demonstrated that T-cell-
specific ephrinB1 or ephrinB2 gene knockout (KO) mice have naive
CD4+ cells exhibiting similar ability to differentiate into Th1, Th2,
Th17 and Treg cells to wildtype (WT) control CD4+ cells [40,41].
However, these studies found that ephrinB1 or ephrinB2 KO mice
displayed normal thymus and spleen weight, size and cellularity and
normal T-cell subpopulations in these organs. In addition, the T-cell
progenitors from KO mice repopulated host spleen T-cell pool similar
to WT control mice. T-cell activation, proliferation and differentiation
potential were also similar to that of WT control mice. These
observations suggest that the function of ephrinB1 or ephrinB2 in the
T-cell compartment, could be compensated by other members of the
Eph family. These studies also indicate that ephrinB1 and ephrinB2 are
unlikely to affect peripheral tolerance due to the absence of an
autoimmune phenotype. Collectively, the role of ephrinB1 or ephrinB2
in the regulation of Treg population is not conclusive and further
investigations are required to fully establish the contribution of Eph/
ephrin interactions in Treg activation and function.
Figure 3: EphB/ephrin-B interactions mediate MSC suppression of
activated T-cells. EphB2/ephrinB1 and ephrinB2/EphB4
interactions play an important role for MSCmediated T-cell
suppression. The expression levels of immunosuppressive factors,
IDO, TGF-β1 and iNOS expressed by MSC were upregulated.
Conversely, key factors involved in T-cell activation and
proliferation, including TNF-α, IL-2 and IL17, were down-regulated
by T-cells.
Concluding Remarks
In the last few decades, there has been increasing interest in MSC
and their potential use in modulating immune/ inflammatory
responses. However, limited information has been available
concerning the molecular mechanisms responsible for the action of
MSC in these processes. The finding that EphB/ephrinB interactions
contribute to MSCmediated Tcell suppression, has extended our
current understanding of how MSC exert their immunosuppressive
effects on activated T-cells. While MSC have been shown to modulate
the responses of T-cell subsets such as CD4+ T-helper cells, CD8+
cytotoxic T-cells and promote the generation of CD4+CD25+Foxp3
regulatory T-cells [17], further investigations into the role of EphB/
ephrinB interactions in the communication of MSC and these T-cell
populations would provide better therapeutic strategies utilizing Eph
and ephrin molecules to facilitate the therapeutic use of MSC in the
clinic.
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